TAE Life Sciences
PrivateLast Round
Series C
Jun 3, 2024
Est. Valuation
$400M
Total Funding Raised
$40M
Company Overview
TAE Life Sciences operates in Healthcare & Life Sciences and is based in Irvine, California. Its latest recorded funding round was a Series A round in March 2018.
TAE Life Sciences is a biotechnology company that develops biologically targeted radiation therapies utilizing Boron Neutron Capture Therapy (BNCT) to treat invasive and challenging cancers.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Medical Imaging, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TAE Life Sciences Comparables
Compare TAE Life Sciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dawon Medax | 85% | |
| Neutron Therapeutics | 84% | |
| Neuboron Medical Group | 83% |
For institutional investors. Book with your work email.
TAE Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jun 3, 2024 | ||||
| Series B | Jun 2, 2020 | ||||
| Series A | Mar 12, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TAE Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rising Tide Fund | Series B, Series A |
| ARTIS Ventures | Series B, Series A |
| Big Sky Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 21, 2026
Monthly visitors increased 37% MoM.
- Apr 1, 2026
CNAO identified as a key deployment site.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 25, 2026
TAE Life Sciences plans to exhibit at the ASTRO 2026 Annual Meeting in Massachusetts, showcasing its Alphabeam(R) BNCT system and featuring Mirokaï social robot from Enchanted Tools.
- recognized_asSep 10, 2026
TAE Life Sciences receives ISO 13485 certification, an internationally recognized medical-device quality standard, following a comprehensive BSI audit that concludes with zero findings in California on Sep 10th '26.
For institutional investors. Book with your work email.
TAE Life Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TAE Life Sciences's valuation, stock price, and market status.
Is TAE Life Sciences a public or private company?
TAE Life Sciences is a private company.
What is the current stock price of TAE Life Sciences?
TAE Life Sciences is a private company, so its shares have no public market price. Caplight tracks TAE Life Sciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TAE Life Sciences worth (valuation)?
TAE Life Sciences's valuation is estimated at $400.0M based on funding round data.
Can I buy TAE Life Sciences stock?
TAE Life Sciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TAE Life Sciences's last funding round?
TAE Life Sciences's most recent funding round was Series C on June 3, 2024.
Who are the main investors in TAE Life Sciences?
Key investors in TAE Life Sciences include ARTIS Ventures.
Will TAE Life Sciences IPO soon?
No public IPO plans have been announced for TAE Life Sciences.
How can I track TAE Life Sciences secondary market activity?
Caplight tracks bids, offers, and trades in TAE Life Sciences's shares on secondary markets.